Identification and Morphological Characterization of Features of Circulating Cancer-Associated Macrophage-like Cells (CAMLs) in Endometrial Cancers.

CAMLs CTC endometrial cancers liquid biopsy triple immuno-fluorescence

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
21 Sep 2022
Historique:
received: 24 08 2022
revised: 09 09 2022
accepted: 18 09 2022
entrez: 14 10 2022
pubmed: 15 10 2022
medline: 15 10 2022
Statut: epublish

Résumé

The blood of patients with solid tumors contains circulating tumor-associated cells, including epithelial cells originating from the tumor mass, such as circulating tumor cells (CTCs), or phagocytic myeloid cells (differentiated monocytes), such as circulating cancer-associated macrophage-like cells (CAMLs). We report for the first time the identification and in-depth morphologic characterization of CAMLs in patients with endometrial cancers. We isolated CAMLs by size-based filtration on lithographically fabricated membranes followed by immunofluorescence, using a CD45+/CK 8,18,19+/EpCAM+/CD31+/macrophage-like nuclear morphology, from > 70 patients. Irrespective of the histological and pathological parameters, 98% of patients were positive for CAMLs. Two size-based subtypes of CAMLs, <20 µm (tiny) and >20 µm (giant) CAMLs, of distinctive polymorphic morphologies with mononuclear or fused polynuclear structures in several morphological states were observed, including apoptotic CAMLs, CAML−WBC doublets, conjoined CAMLs, CAML−WBC clusters, and CTC−CAML−WBC clusters. In contrast, CAMLs were absent in patients with non-neoplastic/benign tumors, healthy donors, and leucopaks. Enumerating CTCs simultaneously from the same patient, we observed that CTC-positive patients are positive for CAMLs, while 55% out of all CAML-positive patients were found positive for CTCs. Our study demonstrated for the first time the distinctive morphological characteristics of endometrial CAMLs in the context of the presence of CTCs in patients.

Identifiants

pubmed: 36230499
pii: cancers14194577
doi: 10.3390/cancers14194577
pmc: PMC9558552
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Avera McKennan Hospital &amp; University Health Center
ID : NA

Références

Annu Rev Pathol. 2020 Jan 24;15:123-147
pubmed: 31530089
Biomedicines. 2022 Mar 02;10(3):
pubmed: 35327389
Methods Mol Biol. 2008;475:149-61
pubmed: 18979243
PLoS One. 2015 Aug 12;10(8):e0134320
pubmed: 26267609
Adv Cancer Res. 2008;101:397-444
pubmed: 19055949
Clin Cancer Res. 2017 Oct 1;23(19):5948-5958
pubmed: 28679765
J Clin Oncol. 2005 Feb 10;23(5):953-64
pubmed: 15598976
JCO Precis Oncol. 2022 Mar;6:e2100378
pubmed: 35417204
Cancers (Basel). 2022 Jun 10;14(12):
pubmed: 35740537
Int J Mol Sci. 2020 Mar 09;21(5):
pubmed: 32182935
PLoS One. 2012;7(3):e33093
pubmed: 22427958
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Crit Rev Oncog. 2013;18(1-2):43-73
pubmed: 23237552
Science. 2004 Feb 13;303(5660):1007-10
pubmed: 14963329
Cytometry A. 2018 Dec;93(12):1246-1250
pubmed: 30369050
Biomark Res. 2021 Oct 9;9(1):72
pubmed: 34625124
Sci Rep. 2018 Jun 21;8(1):9484
pubmed: 29930346
Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17253-8
pubmed: 24101477
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Int J Mol Sci. 2016 Sep 30;17(10):
pubmed: 27706044
BMC Cancer. 2015 Nov 20;15:922
pubmed: 26585897
J Transl Med. 2020 Nov 4;18(1):413
pubmed: 33148307
Nat Rev Immunol. 2008 Dec;8(12):958-69
pubmed: 19029990
Cell. 2006 Jan 27;124(2):263-6
pubmed: 16439202
Cancer Res. 2007 Mar 15;67(6):2649-56
pubmed: 17363585
PLoS One. 2017 Sep 28;12(9):e0184451
pubmed: 28957348
Contrib Microbiol. 2006;13:138-155
pubmed: 16627963
Cells. 2018 Dec 29;8(1):
pubmed: 30597927
Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3514-9
pubmed: 24550495
J Thorac Oncol. 2020 Sep;15(9):1460-1471
pubmed: 32416323
Anticancer Res. 2020 Oct;40(10):5679-5685
pubmed: 32988893
Curr Cancer Drug Targets. 2018;18(6):514-521
pubmed: 29189162
Chromosoma. 2017 Mar;126(2):195-212
pubmed: 27631793
Mol Cancer. 2019 Mar 30;18(1):64
pubmed: 30927925
J Transl Med. 2016 Jul 02;14(1):198
pubmed: 27369977
NPJ Precis Oncol. 2021 Mar 19;5(1):25
pubmed: 33742084

Auteurs

Raed Sulaiman (R)

Department of Pathology, Avera Cancer Institute, Sioux Falls, SD 57105, USA.

Pradip De (P)

Translational Oncology Laboratory, Avera Research Institute, Sioux Falls, SD 57105, USA.
Department of Internal Medicine, University of South Dakota SSOM, Sioux Falls, SD 57069, USA.

Jennifer C Aske (JC)

Translational Oncology Laboratory, Avera Research Institute, Sioux Falls, SD 57105, USA.

Xiaoqian Lin (X)

Translational Oncology Laboratory, Avera Research Institute, Sioux Falls, SD 57105, USA.

Adam Dale (A)

Translational Oncology Laboratory, Avera Research Institute, Sioux Falls, SD 57105, USA.

Ethan Vaselaar (E)

Translational Oncology Laboratory, Avera Research Institute, Sioux Falls, SD 57105, USA.

Cheryl Ageton (C)

Department of Research Oncology, Avera Cancer Institute, Sioux Falls, SD 57105, USA.

Kris Gaster (K)

Outpatient Cancer Clinics, Avera Cancer Institute, Sioux Falls, SD 57105, USA.

Luis Rojas Espaillat (LR)

Department of Gynecologic Oncology, Avera Cancer Institute, Sioux Falls, SD 57105, USA.

David Starks (D)

Department of Gynecologic Oncology, Avera Cancer Institute, Sioux Falls, SD 57105, USA.

Nandini Dey (N)

Translational Oncology Laboratory, Avera Research Institute, Sioux Falls, SD 57105, USA.
Department of Internal Medicine, University of South Dakota SSOM, Sioux Falls, SD 57069, USA.

Classifications MeSH